Research
Hormonal
The mean weight loss after 6 months of semaglutide treatment was 12.3 kg, equivalent to 10.9%.
Practitioners can expect continued weight loss in patients treated with semaglutide over 6 months.
StrongSupportsmedium confidence
The mean (SD) weight loss after 6 months was 12.3 (6.6) kg, equivalent to a mean (SD) weight loss of 10.9% (5.8%) (P < .001 from baseline).
Why this rating
Based on the cohort study design and sample size.
Source
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
Wissam Ghusn et al. · JAMA Network Open · 2022
DOI 10.1001/jamanetworkopen.2022.31982
cohort · n=408Cited 216×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →